-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Business and Investments
Latest From Business and Investments
Novavax gets NIH grant
Novavax, Inc. (NASDAQ:NVAX) has received a Small Business and Innovation Research grant from the National Institute of Allergy and Infectious Diseases. The grant will support a segment of the Company’s preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine. As previously announced, Novavax has an RSV vaccine candidate in preclinical development, which is directed against a protein on the surface of the virus, the “F” or “fusion” protein. The grant, valued at approximately Read More >
Canadian patent strengthens IP for Allon’s 2nd technology platform
Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a Canadian patent covering the chemical composition of the Company’s preclinical-stage peptide AL-209 and its use in protecting against Alzheimer’s disease and other degenerative diseases. The Company said AL-209 has demonstrated highly potent neuroprotective activity in preclinical studies where it has been shown to block the effect of toxic Read More >
Hana Biosciences completes private placement
Hana Biosciences (OTCBB:HNAB) has completed its previously disclosed private placement of units of its securities consisting of shares of common stock and warrants. Hana realized total gross cash proceeds of approximately $12.4 million. Net proceeds of the offering will be used to support completion of Hana’s pivotal Phase 2 clinical trial (rALLy) of Marqibo in adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in second relapse or who failed two Read More >
Podcast with Joyce Cramer, Epilepsy Therapy Project
Biotech-Now’s Tracy Krughoff speaks with Joyce Cramer, president of the Epilepsy Therapy Project about the upcoming BIO Investor Forum and what this advocacy group looks for in terms of companies and projects. Listen to the podcast.
Targacept announces pricing of common stock offering
Targacept, Inc. (NASDAQ: TRGT) announced that the recently announced underwritten public offering of 2,200,000 shares of its common stock has been priced at a price to the public of $21.00 per share. As previously announced, Deutsche Bank Securities will act as sole manager for the offering and Targacept has granted Deutsche Bank Securities an option to purchase an additional 320,000 shares of common stock to cover over-allotments, if any. Read the release.
